CIK 0001022899 · Non-accelerated filer<br>Smaller reporting company
Protagenic Therapeutics, Inc.new
Sign in to watch- Ticker
- PTIX
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 061390025
- Phone
- (212) 994-8200
- Business address
- 149 FIFTH AVENUE, SUITE 500, NEW YORK, NY, 10010
- Former names
- Atrinsic, Inc., NEW MOTION, INC., MPLC, Inc., MILLBROOK PRESS INC
- Open-market buys, last 90 days
- $23,756
- in 3 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$23,756. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2009-06-25 | ZAREF ANDREW Chief Financial Officer | Grant or award · Restricted Stock Units | +200,000 | 200,000 | ||
| 2009-06-25 | Greenberger Zachary Chief Technology Officer | Returned to the company · Stock Option (Right to Buy) | −50,000 | 0 | ||
| 2009-06-25 | Greenberger Zachary Chief Technology Officer | Grant or award · Restricted Stock Units | +16,667 | 16,667 | ||
| 2009-06-25 | DYNE MARK Director | Grant or award | +3,892 | 3,892 | ||
| 2009-06-25 | Katz Burton Chief Executive Officer | Returned to the company · Stock Option (Right to Buy) | −300,000 | 0 | ||
| 2009-06-25 | Katz Burton Chief Executive Officer | Grant or award · Restricted Stock Units | +100,000 | 100,000 | ||
| 2009-06-25 | Katz Burton Chief Executive Officer | Grant or award · Restricted Stock Units | +275,000 | 275,000 | ||
| 2009-06-25 | BURSTEIN LAWRENCE Director | Grant or award | +3,892 | 14,033 | ||
| 2008-11-25 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +25,000 | $1.17 | $29K | 2,338,170 |
| 2008-08-29 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +25,000 | $4.03 | $101K | 2,313,170 |
| 2008-07-14 | ZAREF ANDREW Chief Financial Officer | Grant or award · Options to Purchase Common Stock | +200,000 | 200,000 | ||
| 2008-06-13 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +10,000 | $4.30 | $43K | 2,288,170 |
| 2008-06-11 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +10,000 | $4.36 | $44K | 2,278,170 |
| 2008-06-10 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +10,000 | $4.31 | $43K | 2,268,170 |
| 2008-06-05 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +10,000 | $4.21 | $42K | 2,258,170 |
| 2008-06-02 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +35,000 | $4.00 | $140K | 2,248,170 |
| 2008-05-30 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +35,000 | $4.56 | $160K | 2,213,170 |
| 2008-02-05 | Trinad Capital Master Fund Ltd. Director | Grant or award | +676,072 | 2,178,170 | ||
| 2008-02-04 | STOLLMAN ANDREW President | Other acquisition | +443,085 | 443,085 | ||
| 2008-02-04 | STOLLMAN ANDREW President | Grant or award · Stock Option (Right to Buy) | +273,809 | 273,809 |
Page 7 of 10 · 196 trades